In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper knockoff versions of popular weight loss drugs, Novo Nordisk will not have to | A federal district court in Texas will allow Novo Nordisk to intervene in a lawsuit pitting compounders against the FDA.
Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices. The ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...
Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses ...
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...
Obesity drugs, durable revenue bringing Big Money investors to Eli Lilly and Company (LLY).
Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support.
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...
What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback